Nature vs PLoS One: Which Should You Submit To?

Evidence basis: we checked Nature's current metrics page, Nature Portfolio open-access pricing, PLOS ONE publication fees, PLOS ONE submission guidance, and the dedicated PLOS ONE JIF guide. The decision this page helps with is not "which journal is better." It is whether your current manuscript should test the highest-prestige editorial gate or move directly to a soundness-first open-access journal.

Across Manusights fit reviews, this comparison usually comes up after a team receives a high-tier rejection or before a senior author decides whether to spend one more month on a prestige attempt. The useful answer is rarely "Nature or PLOS ONE only." It is the tier between them: Nature Communications, Science Advances, PNAS, Scientific Reports, a field journal, or PLOS ONE.

Nature's JIF is 56.1 versus PLOS ONE's 2.8. This is a massive gap. Nature is a prestige filter with global recognition. PLOS ONE is a legitimate open-access megajournal designed around technical soundness, not elite selectivity.

For career impact, Nature can be transformative. Publishing there reshapes how hiring committees, grant reviewers, and collaborators read the work. PLOS ONE is different: it shows that the study passed peer review and is openly discoverable, but it will not carry the same prestige signal in competitive faculty or fellowship contexts.

Nature explicitly rejects papers that don't represent major conceptual breakthroughs. The model is "accept only the best." Editors are gatekeepers, rejecting roughly 94% of submissions before or after peer review. The question is always: "Is this a paradigm-shifting discovery?"

PLOS ONE uses a fundamentally different approach. It accepts papers based on scientific rigor, not predicted importance. If your methodology is sound, your results are clear, and your conclusions are justified, PLOS ONE considers it for publication. The questions are: "Is the science valid?" and "Is it interpretable?" - not "Will it change the field?"

Practically: a study that provides a negative result would likely be desk-rejected at Nature but may be publishable in PLOS ONE if the design and reporting are strong. A well-executed methods paper can be rejected at Nature for being incremental but accepted at PLOS ONE if it is useful and technically sound. A narrow disease-mechanism study may belong in PLOS ONE or a specialist journal rather than Nature.

Both journals accept research across sciences. Nature leans toward multidisciplinary work that speaks to broad audiences. PLOS ONE is open to narrower, specialized studies if the research is methodologically sound. If your work matters mainly to a subfield and does not create a broad conceptual change, PLOS ONE or a specialist journal is usually more realistic.

Nature: Nature does not present a simple acceptance-rate row on its public metrics page. The better public signals are selectivity by editorial model, median 8 days to first editorial decision, and 321 days from submission to acceptance for papers that make it through the full path.

PLOS ONE: PLOS reports a 31% acceptance rate in its latest annual metrics set. That is not automatic acceptance. It means methods, ethics, reporting, scope, and data availability still block a large share of submissions.

The selectivity difference reflects each journal's mission. Nature is intentionally exclusive. PLOS ONE is intentionally inclusive, but the inclusion is for sound science, not incomplete science.

Nature: The public metrics page reports 8 median days to first editorial decision and 321 median days from submission to acceptance. A fast first decision can still mean a desk rejection; a successful paper can spend much longer in review and revision.

PLOS ONE: PLOS reports 40 days to first decision and 213 days to publication in its annual metrics set. The workflow can be faster than prestige-journal cascades, but it is not a guaranteed 6-week route.

If speed matters for job applications or grant timelines, PLOS ONE is often the more pragmatic choice. The strongest reason is not that review is instant. It is that the editorial bar is clearer: technical soundness, not broad significance.

Nature: Subscription model. No APC for authors. Published papers are behind a paywall initially, though authors can self-archive preprints.

PLOS ONE: Full open access. APC is $2,477 for standard articles in current PLOS pricing. Any paper published is free to read globally. PLOS has institutional partnership, Research4Life, waiver, and discount routes that can change what an author actually pays.

The cost math: If you publish in Nature through the subscription route, there is no standard APC. If your funder or institution requires gold OA, Nature Portfolio lists Nature at EUR 10,850. PLOS ONE costs $2,477 for standard articles, or less with eligible institutional or waiver coverage.

Nature is universally recognized as elite. Hiring committees, grant panels, and department heads immediately recognize the prestige. PLOS ONE is respected as a legitimate place to publish rigorous work, but it is not usually read as an elite achievement. This matters in competitive fields and matters less in settings where peer-reviewed publication and discoverability are the main goals.

In some fields (computer science, for example), PLoS One is less common and less prioritized than discipline-specific journals. In biomedical and life sciences, PLoS One is mainstream and well-regarded.

Breakthrough research: Try Nature. You have an obligation to yourself to test the highest tier if you think you've made a major discovery.

Strong, novel work that's not a breakthrough: Consider both. If you need publication fast and want open access, start with PLoS One. If you want to test whether the work is breakthrough-level, try Nature first and use PLoS One as your backup.

Solid science, narrow focus, incremental advance: PLoS One is your target. It's designed for this. You'll publish faster, likely with fewer revision rounds, and your work will reach a global open-access audience.

Under time pressure: PLoS One. The timeline advantage is real. If you need publication within 2 months, PLoS One gives you a reasonable shot. Nature will likely result in desk rejection or a months-long process.

Limited funding for open access: Nature avoids APCs. But acceptance is so unlikely that PLoS One may be more pragmatic despite the APC.

Many researchers use this logic: If I'm confident this is a breakthrough, I submit to Nature. If Nature desk-rejects (which is likely), I immediately reformat and submit to PLoS One. The Nature rejection feedback (if any) can sometimes improve the PLoS One submission.

Some skip Nature entirely and go to PLoS One to ensure publication quickly, then submit stronger future work to Nature.

Nature and PLoS One aren't in competition; they serve different functions. Nature publishes paradigm-shifting discoveries. PLoS One publishes peer-reviewed, rigorous science without the breakthrough requirement. Both are legitimate, peer-reviewed publications. The choice depends on your paper's impact level, your timeline, your budget, and your career stage.

Publishing in PLOS ONE is not settling. It's a strategic choice to get valid science into the literature where it will be read and used by researchers worldwide.

Most researchers aren't actually choosing between Nature and PLOS ONE. They're trying to calibrate which tier their paper fits. Here's the cascade:

If Nature desk-rejects your paper (94% chance), don't drop straight to PLOS ONE. Consider whether it fits a Nature-branded specialty journal, Nature Communications, Science Advances, or PNAS first. Each tier has different editorial requirements and very different APCs.

A Nature vs PLOS ONE tier placement and fit check can identify which tier your paper actually fits before you enter the submission lottery.